Assessing Qualys (QLYS) Valuation After Recent Modest Pullback in a Shifting Security Software Landscape

Qualys (QLYS) has seen its stock slip about 1% over the past week, following a three-month decline of nearly 13%. Investors might be asking what’s next as Qualys looks to gain stability in a competitive software security landscape.

See our latest analysis for Qualys.

While Qualys has faced a moderate pullback recently, that comes after a year of total shareholder return near break-even. This reflects a period where positive momentum has faded and the market is weighing growth expectations against a shifting security software landscape.

If you want to expand your search beyond Qualys, it could be a smart move to explore fast growing stocks with high insider ownership.

With shares trading around 8% below analyst targets and recent growth appearing modest, the key question for investors is whether Qualys is undervalued at current levels or if the market has already factored in its future prospects.

Advertisement

Most Popular Narrative: 7% Undervalued

With Qualys closing at $130.78, the most widely followed narrative places its fair value much higher, suggesting today's investors may be missing something big. Let's look at one of the key reasons this valuation stands apart from the market's cautious tone.

Adoption of Qualys' new cloud-native risk operations center (ROC) and Agentic AI platform positions the company as a leading pre-breach risk management provider, offering unified orchestration, automation, and remediation across both Qualys and non-Qualys data. This opens incremental greenfield opportunities and should support higher ARPU and expanded TAM, leading to durable revenue and earnings growth.

Read the complete narrative.

There is a disruptive growth play shaping this valuation. What if a new platform is the lever for dominating emerging cybersecurity budgets? Uncover which bold financial moves this narrative thinks will fuel the next chapter for Qualys.

Result: Fair Value of $141.02 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, rapid shifts in AI security or customer consolidation with larger platforms could present challenges to Qualys’ growth assumptions and threaten its market position.

Find out about the key risks to this Qualys narrative.

Build Your Own Qualys Narrative

If you prefer your own approach or want to dive deeper into the data behind these conclusions, you can craft your own perspective in just a few minutes using our toolkit. Explore insights, review valuation, and truly make it yours with Do it your way.

A great starting point for your Qualys research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Don't wait on the sidelines. The next big opportunity could be right around the corner, and it pays to look beyond just one company for your portfolio.

  • Capture upside in emerging healthcare AI by tapping into these 31 healthcare AI stocks, where medical innovation intersects with artificial intelligence to transform patient outcomes and efficiencies.
  • Amplify your returns by targeting these 19 dividend stocks with yields > 3%, featuring companies with robust yields over 3% that reward you as a shareholder while you watch your investments grow.
  • Accelerate your search for untapped opportunities in high-potential markets through these 3568 penny stocks with strong financials, and uncover fast-moving stocks with the fundamentals to match.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Qualys might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:QLYS

Qualys

Provides cloud-based platform delivering information technology (IT), security, and compliance solutions in the United States and internationally.

Flawless balance sheet with proven track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
48 users have followed this narrative
2 users have commented on this narrative
8 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
188 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0